This study was undertaken to evaluate an assay to assess the risk for
drug-induced immediate hypersensitivity reactions. Groups of five to 1
0 guinea-pigs were given six ip injections of the test compound on day
s 1, 3, 5, 8, 10 and 12. Aluminium hydroxide was also given in the fir
st injection. At day 33, the animals were given an iv injection of the
test compound and the response was recorded by grading the severity o
f clinical symptoms. Cutaneous passive anaphylaxis was also evaluated
in six naive guinea pigs using Evans blue and sera collected from trea
ted animals on day 26. A panel of six positive model compounds (ovalbu
min, aprotinin, chymopapain, tetracosactide, cyanocobalamin and procai
ne), and the negative compound Ribomunyl were tested. Positive systemi
c and/or cutaneous anaphylactic responses were observed with ovalbumin
, aprotinin, chymopapain and tetracosactide whereas no responses were
noted with cyanocobalamin, procaine and Ribomunyl. Our results suggest
that this protocol can help differentiate positive model compounds (k
nown to induce reactions in man) from negative model compounds, provid
ed that their molecular weight is large enough, but that it is not app
licable to substances of low molecular weight.